Clinical and economic burden of otitis media in children under 5 years of age in the United States: A retrospective study DOI Creative Commons

Lilia Ben Debba,

Dominique Derreumaux,

Germain Lonnet

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Oct. 18, 2024

Reductions in all-cause otitis media (OM) following widespread pneumococcal conjugate vaccine use have plateaued. Granular burden of disease data are needed to guide evaluation and implementation new measures targeting OM prevention. We conducted a retrospective study assess the incidence treatment costs OM, tympanostomy tube placement (TTP), hearing loss children aged <5 years United States (US). episodes TTP between 2016 2017 were identified IBM MarketScan Commercial Claims Encounters, Medicare Supplemental Coordination Benefits, Multi-Medicaid databases using diagnosis codes (ICD-10). The rate per 100,000 person-years (IR) <5-year-olds was 62,726 Commercial/Medicare 55,874 Medicaid. IRs peaked at 9-<12 months (115,552 110,960, respectively). Approximately 5% 4% respective had (IR 3233 2404). Around 2% with 1468 1109, respectively), whom 41% TTP. estimated that there 11.1 million 2020 costing USD 4.8 billion. 243,618 direct total cost 637 million, or 13% overall cost. clinical economic attributable US high during period. Novel approaches improve broaden vaccine-induced protection against its complications. results could policymakers considering age-specific interventions reduce burden.

Language: Английский

Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population DOI Creative Commons
Min Huang, Tianyan Hu, Jessica Weaver

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(1), P. 135 - 135

Published: Jan. 6, 2023

This study evaluated the clinical and economic impact of routine pediatric vaccination with 15-valent pneumococcal conjugate vaccine (PCV15, V114) compared 13-valent PCV (PCV13) from a societal perspective in United States (US). A Markov decision-analytic model was constructed to estimate outcomes for entire US population over 100-year time horizon. The estimated V114 versus PCV13 on disease (PD) incidence, post meningitis sequalae, deaths, taking herd immunity effects into account. effectiveness extrapolated observed data PCV7 trials. Costs (2021$) included acquisition administration costs, direct medical costs PD treatment, non-medical indirect were discounted at 3% per year. In base case, prevented 185,711 additional invasive disease, 987,727 all-cause pneumonia, 11.2 million acute otitis media cases, PCV13. led expected gains 90,026 life years 96,056 quality-adjusted total saving $10.8 billion. Sensitivity analysis showed consistent results plausible values key inputs assumptions. findings suggest that is cost-saving option program.

Language: Английский

Citations

11
Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States DOI
Namrata Prasad, Charles Stoecker,

Wei Xing

et al.

Vaccine, Journal Year: 2023, Volume and Issue: 41(18), P. 2914 - 2921

Published: April 1, 2023

Language: Английский

Citations

11
Otitis Media in Young Children DOI
Nader Shaikh

New England Journal of Medicine, Journal Year: 2025, Volume and Issue: 392(14), P. 1418 - 1426

Published: April 9, 2025

Language: Английский

Citations

0
Otitis Media DOI
Paula A. Tähtinen, Nader Shaikh

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 156 - 167.e2

Published: Jan. 1, 2025

Citations

0
Prevalence and Outpatient Clinical Diagnostic Approaches for Common Acute Respiratory Tract Infections in Children Under Five Years of Age: A Cross-Sectional Study DOI Creative Commons
Munanura Turyasiima, Gloria Kiconco, Walufu Ivan Egesa

et al.

Pediatric Health Medicine and Therapeutics, Journal Year: 2024, Volume and Issue: Volume 15, P. 49 - 57

Published: Jan. 1, 2024

Background: Acute respiratory tract infections are among the leading causes of child morbidity and mortality worldwide. Although diagnosis acute requires simple outpatient medical techniques care, it is still misdiagnosed primary care physicians, to delayed treatment increased mortality. This study described prevalence common that effectively detect diagnose children presenting with symptoms healthcare physicians in remote settings. Patients Methods: descriptive cross-sectional was conducted at pediatric clinic a tertiary hospital western Uganda April, May June 2019. A total 896 aged 2– 59 months attending were recruited consecutively into examined for presence infection. Participants’ sociodemographic clinical data collected through history taking examination using validated Ministry Health checklist (FORM 5). The outcome variable an upper or lower condition. Data analyzed STATA version 13.0 (StataCorp, College Station, USA) summarized statistics. Results: overall period 2 36.9% (36,942 per 100,000 population). Upper 24.8% more than infections. most frequent infection this setting cold (52%), followed by tonsillopharyngitis (10.7%), while pneumonia (26%) Conclusion: contribute high burden disease clinics. Simple, affordable, approved diagnostic involve physical systems can precisely resource-limited settings where there no access sophisticated equipment. Keywords: infections, diagnosis,

Language: Английский

Citations

2
Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998–2019 DOI Creative Commons
Salini Mohanty, Nicolae Done, Qing Liu

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(11), P. 2758 - 2769

Published: March 13, 2024

Pneumococcal disease (PD) is a major cause of morbidity and mortality among children, particularly in the youngest age groups. This study aimed to assess incidence PD over time by group young children with commercial or Medicaid coverage US. Episodes invasive pneumococcal (IPD), all-cause pneumonia (ACP), acute otitis media (AOM) were identified MarketScan® Commercial claims databases using diagnosis codes aged ≤ 48 months confirmed date birth (DoB), at any during period (1998–2019). DoB was assigned for delivery child's mother's medical ensure accurate determination. Annual rates (IRs) calculated as number episodes/100,000 person-years (PY) IPD ACP episodes/1,000 PY AOM, 0–6, 7–12, 12–24, 25–48 months. IRs declined from 53 7 between 1998 2019 commercially-insured 58 9 2001 Medicaid-insured children. 5,600 3,952 PY, 6,706 4,521 respectively, these periods. In both populations, 0–6 had highest inpatient ACP. AOM 1,177 738 (commercially-insured) 633 624 (Medicaid-insured), higher rural vs. urban areas all manifestations. Incidence IPD, ACP, decreased insurance 2019. However, burden remained substantial, annual most common old, followed 7–12-month group.

Language: Английский

Citations

2
A dynamic transmission model for assessing the impact of pneumococcal vaccination DOI Creative Commons
Tufail Malik, Kevin M. Bakker, Rachel J. Oidtman

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: June 13, 2024

Abstract Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children every year across the globe. Multiple vaccines exist prevent pneumococcal disease, with each vaccine covering variable number of 100 known serotypes. Due to high effectiveness these vaccines, new conjugate (PCV) introduction has resulted in decrease vaccine-type disease and shift serotype distribution towards non-vaccine types phenomenon called replacement. Here, an age-structured compartmental model was created capture carriage transmission dynamics SP subsequent progression presence introduced at different times age groups. The incorporates co-colonization competition, which drives replacement by types. calibrated historical age- serotype-specific invasive (IPD) data from United States. Vaccine-specific coverage were integrated accordance recommended timelines for group. Demographic parameters derived US-population-specific databases, while population mixing patterns informed US-specific published literature on age-group based matrices. then used project epidemiological impact PCV15, 15-valent vaccine, compared status quo vaccination PCV13 demonstrated value added serotypes PCV15. Projections revealed PCV15 would reduce IPD incidence 6.04% (range: 6.01% 6.06%) over 10 years when PCV13.

Language: Английский

Citations

2
Characterization of Streptococcus pneumoniae isolates obtained from the middle ear fluid of US children, 2011–2021 DOI Creative Commons
Lindsay R. Grant,

Kevin Apodaca,

Lalitagauri M. Deshpande

et al.

Frontiers in Pediatrics, Journal Year: 2024, Volume and Issue: 12

Published: July 15, 2024

Pneumococcal conjugate vaccines (PCVs), including higher valency such as PCV20, have the potential to reduce pediatric otitis media. We assessed serotype distribution, PCV coverage, and antimicrobial susceptibility of

Language: Английский

Citations

2
Incidence, antimicrobial prescribing practice, and associated healthcare costs of paediatric otorrhoea in primary care in the UK: a longitudinal population study DOI Creative Commons
Elliot Heward, Eleni Domzaridou, Sean P. Gavan

et al.

British Journal of General Practice, Journal Year: 2024, Volume and Issue: 75(751), P. e113 - e121

Published: Aug. 20, 2024

Paediatric otorrhoea (PO) is a symptom-based diagnosis encompassing acute and chronic ear infections that cause in children young people (CYP). To understand the burden of PO on primary care services. This was longitudinal population study UK care. Data from Clinical Practice Research Datalink (CPRD Aurum), January 2005 to December 2019, analysed. CYP <17 years age with were included. Standardised annual incidence presentation rates estimated. Poisson regression modelling used determine risk ratios comparing sex, age, Index Multiple Deprivation (IMD). A probabilistic simulation scaled-up estimates for population. The cohort included 6 605 193 CYP, observed over 32 942 594 person-years. There 80 454 incident cases 106 318 presentations during 15-year period, equating standardised per 1000 patient-years 2.42 (95% confidence interval [CI] = 2.40 2.44) 3.15 CI 3.13 3.17), respectively. In this equates 41 141 appointments year. Incidence higher males, those aged 0-2 years, living least deprived quintile. Treatment involved oral antibiotics (57.1%, 45 931/80 454), no prescription (28.1%, 22 569/80 topical (9.7%, 7797/80 545), or combination (4.9%, 3910/80 545). cost NHS estimated at £1.97 million authors' knowledge, first population-based investigating demonstrates Antimicrobial prescribing predominantly follows National Institute Health Care Excellence guidelines using amoxicillin. Aminoglycosides are most frequently prescribed antibiotic despite concern ototoxicity.

Language: Английский

Citations

2
Estimating population-based incidence of community-acquired pneumonia and acute otitis media in children and adults in Ontario and British Columbia using health administrative data, 2005–2018: a Canadian Immunisation Research Network (CIRN) study DOI Creative Commons
Sharifa Nasreen, Jun Wang, Manish Sadarangani

et al.

BMJ Open Respiratory Research, Journal Year: 2022, Volume and Issue: 9(1), P. e001218 - e001218

Published: June 1, 2022

Background There is a paucity of data on the burden full spectrum community-acquired pneumonia (CAP) and acute otitis media (AOM) from outpatient inpatient settings across age spectrum. Methods We conducted population-based retrospective study in Ontario British Columbia (BC), Canada, to estimate incidence rate CAP AOM children adults over 14-year period using health administrative databases. cases were identified physician consultation hospitalisation both provinces, emergency department visit Ontario. Results During 2005–2018, had 3 607 124 CAP, 172 290 bacterial 7814 pneumococcal pneumonia, 8 026 971 cases. The declined 3077/100 000 2005 2604/100 2010 before increasing 2843/100 2018; also 178/100 112/100 149/100 2018. decreased 4192/100 3178/100 BC 970 455 317 913 35 287 2 022 871 2214/100 1964/100 2176/100 increased 442/100 981/100 3684/100 2398/100 with older (≥65 years) highest oldest cohort aged ≥85 years after 13-valent conjugate vaccine (PCV13) programme provinces. Hospitalised slightly but non-hospitalised during PCV13 period. No consistent direct benefit was observed paediatric population. Conclusions substantial BC. Indirect benefits childhood PCV vaccination polysaccharide have not substantially adults.

Language: Английский

Citations

9